Department of Chemistry and Chemical Biology and the Brockhouse Institute for Materials Research, McMaster University, Hamilton, Ontario, Canada.
Rapid Dose Therapeutics, Corp., Burlington, Ontario, Canada.
J Pharm Sci. 2024 May;113(5):1220-1227. doi: 10.1016/j.xphs.2023.11.011. Epub 2023 Nov 19.
Rapidly dissolving polymer thin films, or oral thin films (OTFs), have recently emerged as an improved oral drug delivery vehicle with its ability to bypass liver first pass metabolism, longer shelf-life, and simpler transport and distribution requirements, compared to traditional tablets and liquid formulations. Loratadine (LOR), an antihistamine commonly used to treat allergic rhinitis, undergoes liver first pass metabolism and is a prime candidate for incorporation within an OTF. However, loratadine is a BCS II drug with low aqueous solubility. Herein, the solubility of loratadine was improved by complexation with methyl β-cyclodextrin (MBCD) by co-evaporation of 2:1, 1:1, and 1:2 LOR:MBCD ratios and incorporation into a pullulan-based OTF at 4 wt% by solvent casting at 50 °C for 30 - 35 min. A therapeutically relevant 10 mg LOR dose could be prepared in a 3 cm by 3 cm OTF. The feasibility of complexation was observed with a B-type phase solubility diagram, and complexation itself was confirmed via differential scanning calorimetry (DSC) by disappearance of the LOR melting peak, Fourier-transform infrared spectroscopy (FTIR) by shifting of the C=O peak, via H NMR spectroscopy by downfield shifting and change in peak multiplicity of the LOR aromatic protons, and via diffusion-ordered spectroscopy by a decrease in the diffusion coefficient of LOR:MBCD complex. LOR:MBCD could be incorporated homogeneously throughout an OTF, and LOR:MBCD OTFs exhibited reasonable mechanical strength and endured 12 ± 3 folds before breaking. LOR:MBCD OTFs disintegrated within 38 ± 10 s. The cumulative in vitro release of LOR:MBCD OTFs peaked at 80 % within 3-4 min of dissolution, and LOR in LOR:MBCD OTFs exhibited permeability across a 0.22 μm nitrocellulose membrane, demonstrating its applicability as a rapid drug delivery vehicle.
快速溶解聚合物薄膜,或口腔薄膜(OTF),最近作为一种改进的口服药物输送载体出现,与传统片剂和液体配方相比,其具有绕过肝脏首过代谢、更长的保质期以及更简单的运输和分配要求的能力。氯雷他定(LOR)是一种常用于治疗过敏性鼻炎的抗组胺药,经历肝脏首过代谢,是 OTF 中包含的主要候选药物。然而,氯雷他定是一种 BCS II 药物,水溶性低。在此,通过将 2:1、1:1 和 1:2 LOR:MBCD 比例的洛他定与甲基-β-环糊精(MBCD)共蒸发来改善洛他定的溶解度,并将其以 4wt%的浓度掺入基于普鲁兰的 OTF 中通过在 50°C 下浇铸 30-35 分钟来制备。可以在 3cm×3cm 的 OTF 中制备治疗相关的 10mg LOR 剂量。通过 B 型相溶解度图观察到络合的可行性,并通过差示扫描量热法(DSC)通过消失的 LOR 熔融峰、傅里叶变换红外光谱(FTIR)通过 C=O 峰的移动、通过 H NMR 光谱通过 LOR 芳香质子的场位移和峰多重性的变化以及通过扩散有序光谱通过 LOR:MBCD 络合物的扩散系数的降低来确认络合本身。LOR:MBCD 可以均匀地掺入 OTF 中,并且 LOR:MBCD OTF 表现出合理的机械强度,并且在断裂之前可以承受 12±3 倍的折叠。LOR:MBCD OTF 在 38±10s 内崩解。LOR:MBCD OTF 的累积体外释放在溶解后 3-4 分钟内达到 80%的峰值,并且 LOR 在 LOR:MBCD OTF 中的渗透性穿过 0.22μm 硝酸纤维素膜,证明其作为快速药物输送载体的适用性。